Published in J Biol Chem on December 18, 2006
Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes (2007) 1.67
Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res (2013) 1.61
Natural antisense transcript for hyaluronan synthase 2 (HAS2-AS1) induces transcription of HAS2 via protein O-GlcNAcylation. J Biol Chem (2014) 1.54
Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol (2008) 1.53
The thrombospondins. Cold Spring Harb Perspect Biol (2011) 1.52
Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.22
Aryl hydrocarbon receptor is activated by glucose and regulates the thrombospondin-1 gene promoter in endothelial cells. Circ Res (2008) 1.11
Exercise-induced expression of angiogenic growth factors in skeletal muscle and in capillaries of healthy and diabetic mice. Cardiovasc Diabetol (2008) 1.06
Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates igf-I signaling in vivo. Diabetes (2008) 1.03
Research resource: expression profiling reveals unexpected targets and functions of the human steroid receptor RNA activator (SRA) gene. Mol Endocrinol (2010) 1.01
O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS One (2010) 1.00
Role of UDP-N-acetylglucosamine (GlcNAc) and O-GlcNAcylation of hyaluronan synthase 2 in the control of chondroitin sulfate and hyaluronan synthesis. J Biol Chem (2012) 0.96
Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. Circ Res (2015) 0.95
Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res (2014) 0.94
Invoking the power of thrombospondins: regulation of thrombospondins expression. Matrix Biol (2014) 0.92
Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol (2010) 0.91
Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biol (2014) 0.90
Novel tissue-specific mechanism of regulation of angiogenesis and cancer growth in response to hyperglycemia. J Am Heart Assoc (2012) 0.88
Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation. Exp Diabetes Res (2010) 0.83
Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J Pharmacol Exp Ther (2008) 0.82
Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus. Korean Circ J (2012) 0.81
A novel transcriptional mechanism of cell type-specific regulation of vascular gene expression by glucose. Arterioscler Thromb Vasc Biol (2010) 0.81
Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol (2015) 0.80
Glucose downregulation of PKG-I protein mediates increased thrombospondin1-dependent TGF-{beta} activity in vascular smooth muscle cells. Am J Physiol Cell Physiol (2010) 0.78
The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest (2017) 0.77
Proangiogenic Properties of Thrombospondin-4. Arterioscler Thromb Vasc Biol (2015) 0.77
Anti-atherogenic effect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro. Nanoscale (2016) 0.76
Inhaled insulin for controlling blood glucose in patients with diabetes. Vasc Health Risk Manag (2007) 0.76
Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice. Sci Rep (2017) 0.75
Feeding sugar to tumors: with a supplement of miR? J Am Heart Assoc (2012) 0.75
Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell (2005) 7.41
Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med (2005) 3.60
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol (2002) 2.22
The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am J Pathol (2004) 1.88
Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol (2003) 1.76
SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem (2007) 1.68
Dynamic reciprocity in the wound microenvironment. Wound Repair Regen (2011) 1.62
Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost (2003) 1.52
Interactions between CD47 and thrombospondin reduce inflammation. J Immunol (2007) 1.46
Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9. J Leukoc Biol (2009) 1.41
Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci (2004) 1.40
Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal (2009) 1.40
Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol (2009) 1.40
Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation (2003) 1.39
Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest (2006) 1.35
Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol (2007) 1.35
Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell (2002) 1.26
Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol (2008) 1.25
Translation mediated by the internal ribosome entry site of the cat-1 mRNA is regulated by glucose availability in a PERK kinase-dependent manner. J Biol Chem (2002) 1.20
Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res (2010) 1.19
Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol (2005) 1.17
Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol (2008) 1.17
The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation. J Bone Miner Res (2002) 1.15
Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2--deficient mice. Blood (2002) 1.14
Mice with a deletion in the first intron of the Col1a1 gene develop age-dependent aortic dissection and rupture. Circ Res (2003) 1.12
Thrombospondin 2 levels are increased in aged mice: consequences for cutaneous wound healing and angiogenesis. Matrix Biol (2004) 1.11
Aryl hydrocarbon receptor is activated by glucose and regulates the thrombospondin-1 gene promoter in endothelial cells. Circ Res (2008) 1.11
Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. Circulation (2003) 1.11
Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res (2005) 1.10
Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J (2012) 1.09
pH-sensitive polymers that enhance intracellular drug delivery in vivo. J Control Release (2002) 1.05
Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am J Pathol (2003) 1.04
Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol (2005) 1.03
Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell (2007) 1.03
Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation (2009) 1.00
Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J Biol Chem (2007) 1.00
Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. Blood (2005) 1.00
Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol (2009) 0.97
Reduced expression of thrombospondins and craniofacial dysmorphism in mice overexpressing Fra1. J Bone Miner Res (2006) 0.96
Megakaryocytes require thrombospondin-2 for normal platelet formation and function. Blood (2003) 0.95
Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. FASEB J (2005) 0.95
Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res (2005) 0.95
Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J Histochem Cytochem (2008) 0.94
SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. J Histochem Cytochem (2005) 0.93
Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in experimental glomerulonephritis in mice. J Am Soc Nephrol (2007) 0.91
Thrombospondin 2 deficiency in pregnant mice results in premature softening of the uterine cervix. Biol Reprod (2003) 0.91
Mice lacking thrombospondin 2 show an atypical pattern of endocortical and periosteal bone formation in response to mechanical loading. Bone (2005) 0.89
Novel tissue-specific mechanism of regulation of angiogenesis and cancer growth in response to hyperglycemia. J Am Heart Assoc (2012) 0.88
The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function. J Biol Chem (2006) 0.83
Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc Pathol (2012) 0.83
Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline. Biochem Biophys Res Commun (2003) 0.82
Metaxin deficiency alters mitochondrial membrane permeability and leads to resistance to TNF-induced cell killing. Protein Cell (2010) 0.81
Counterbalancing forces: what is thrombospondin-1 doing in atherosclerotic lesions? Circ Res (2008) 0.81
A novel transcriptional mechanism of cell type-specific regulation of vascular gene expression by glucose. Arterioscler Thromb Vasc Biol (2010) 0.81
Expression in SPARC-null mice of collagen type I lacking the globular domain of the α1(I) N-propeptide results in abdominal hernias and loss of dermal collagen. Matrix Biol (2010) 0.78
Disruption of the thrombospondin-2 gene alters the lamellar morphology but does not permit vascularization of the adult mouse lumbar disc. Arthritis Res Ther (2008) 0.77
MET orchestrates cancer and blood coagulation. Nat Med (2005) 0.76
Vascular complications of diabetes. Curr Pharm Des (2005) 0.75